Literature DB >> 33214689

PTCy and "The Story of the Three Bears".

Vedran Radojcic1, Leo Luznik2.   

Abstract

Entities:  

Year:  2020        PMID： 33214689     DOI： 10.1038/s41409-020-01123-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.

Authors:  Chien-Jung Lin; Justin M Vader; Michael Slade; John F DiPersio; Peter Westervelt; Rizwan Romee
Journal:  Cancer       Date:  2017-03-06       Impact factor: 6.860

2.  Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.

Authors:  Juan Montoro; Pedro Chorão; Leyre Bento; Mónica Cabrero; Carmen Martín; Silvana Novelli; Irene García Cadenas; Gonzalo Gutiérrez; Oriana López-Godino; Christelle Ferrá; Mariana Bastos-Oreiro; Ariadna Pérez; Rocío Parody; José A Pérez Simón; Lucrecia Yañez; Andrés Sánchez; Joud Zanabili; Ma Rosario Varela; Raúl Córdoba; Teresa Zudaire; Ana Jiménez-Ubieto; Jaime Sanz; Ana Sureda; Dolores Caballero; José Luis Piñana
Journal:  Bone Marrow Transplant       Date:  2020-12-12       Impact factor: 5.483

3.  Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Authors:  Laura K Schoch; Kenneth R Cooke; Nina D Wagner-Johnston; Ivana Gojo; Lode J Swinnen; Philip Imus; Ephraim J Fuchs; Mark Levis; Richard F Ambinder; Richard J Jones; Douglas E Gladstone
Journal:  Blood Adv       Date:  2018-09-11

4.  Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.

Authors:  Amy E DeZern; Marianna L Zahurak; Heather J Symons; Kenneth R Cooke; Gary L Rosner; Douglas E Gladstone; Carol Ann Huff; Lode J Swinnen; Philip Imus; Ivan Borrello; Nina Wagner-Johnston; Richard F Ambinder; Leo Luznik; Javier Bolaños-Meade; Ephraim J Fuchs; Richard J Jones; Robert A Brodsky
Journal:  Blood Adv       Date:  2020-04-28

5.  Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.

Authors:  Betül Oran; Guillermo Garcia-Manero; Rima M Saliba; Mansour Alfayez; Gheath Al-Atrash; Stefan O Ciurea; Elias J Jabbour; Rohtesh S Mehta; Uday R Popat; Farhad Ravandi; Amin M Alousi; Tapan M Kadia; Marina Konopleva; Courtney D DiNardo; Katy Rezvani; Elizabeth J Shpall; Padmanee Sharma; Hagop M Kantarjian; Richard E Champlin; Naval Daver
Journal:  Cancer       Date:  2020-03-03       Impact factor: 6.860

6.  Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.

Authors:  Giorgia Battipaglia; Myriam Labopin; Nicolaus Kröger; Antonin Vitek; Boris Afanasyev; Inken Hilgendorf; Johannes Schetelig; Arnold Ganser; Didier Blaise; Maija Itälä-Remes; Jakob R Passweg; Francesca Bonifazi; Jurgen Finke; Annalisa Ruggeri; Arnon Nagler; Mohamad Mohty
Journal:  Blood       Date:  2019-07-03       Impact factor: 22.113

Review 7.  Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil.

Authors:  Charles Herbaux; Reid Merryman; Steven Devine; Philippe Armand; Roch Houot; Franck Morschhauser; Bradley Haverkos
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

8.  Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Authors:  Yvette L Kasamon; Richard F Ambinder; Ephraim J Fuchs; Marianna Zahurak; Gary L Rosner; Javier Bolaños-Meade; Mark J Levis; Douglas E Gladstone; Carol Ann Huff; Lode J Swinnen; William H Matsui; Ivan Borrello; Robert A Brodsky; Richard J Jones; Leo Luznik
Journal:  Blood Adv       Date:  2017-01-06

9.  Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.

Authors:  Marco Mielcarek; Terry Furlong; Paul V O'Donnell; Barry E Storer; Jeannine S McCune; Rainer Storb; Paul A Carpenter; Mary E D Flowers; Frederick R Appelbaum; Paul J Martin
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

10.  Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation.

Authors:  Junichi Sugita; Tomohiko Kamimura; Takayuki Ishikawa; Shuichi Ota; Tetsuya Eto; Takashi Kuroha; Yasuhiko Miyazaki; Hiroaki Kumagai; Keitaro Matsuo; Koichi Akashi; Shuichi Taniguchi; Mine Harada; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2020-09-24       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.